Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

BACKGROUND: Combining bevacizumab with first-line chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC). However, identification of patients benefitting most from bevacizumab remains elusive. The AVADO trial included an extensive optional...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, D W, de Haas, S L, Dirix, L Y, Romieu, G, Chan, A, Pivot, X, Tomczak, P, Provencher, L, Cortés, J, Delmar, P R, Scherer, S J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619079/
https://www.ncbi.nlm.nih.gov/pubmed/23422754
http://dx.doi.org/10.1038/bjc.2013.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619079/
https://www.ncbi.nlm.nih.gov/pubmed/23422754
http://dx.doi.org/10.1038/bjc.2013.69

Ejemplares similares